INTRODUCTION {#s1}
============

Urologic cancer is one of the most common of cancers worldwide, with an estimated incidence of 146,650 new cases and 32,190 deaths in United States in 2017 \[[@R1]\]. Until now, TNM staging is the most commonly used method to predict the prognosis and guide treatment in cancer. However, urologic cancer patients with the same TNM stage may have different clinical prognosis \[[@R2]\]. Thus, this leaves a large space for the development of additional biomarkers to predict the clinical outcome.

Recently, more and more evidence have reported that the development and prognosis of cancer are affected not only by cancer characteristics but also by host systemic inflammatory response \[[@R3], [@R4]\]. In clinical work, the inflammatory response can be evaluated by lots of biomarkers such as neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR) and C-reactive protein, etc.\[[@R5]\]. Now, NLR have been reported to be a prognostic predictor of urologic tumors such as bladder cancer, renal cell cancer, upper tract urothelial cancer (UTUC) and prostate cancer \[[@R6]--[@R10]\]. On the other hand, a growing body of evidence reports that a high PLR was a poor prognostic indicator in various types of cancers including lung cancer, colorectal cancer, gastric cancer and breast cancer \[[@R11]--[@R14]\]. But the prognostic value of PLR in urologic cancer does not reach a consensus. To the best of our knowledge, until now there was no a pooled study to assess the prognostic significance of PLR in urologic cancer.

In this study, we searched the relevant articles and conducted a pooled study to explore the prognostic value of PLR in urologic cancer including renal cancer, UTUC, bladder cancer, prostate cancer and adrenal cancer.

RESULTS {#s2}
=======

Studies characteristics and overall effect {#s2_1}
------------------------------------------

The literature search strategy yielded 255 potentially relevant studies and then 235 citations were excluded. Finally, a total of 20 articles were included in this study \[[@R15]--[@R34]\]. The flow diagram of study selection procedure is shown in Figure [1](#F1){ref-type="fig"}.

![Flow diagram of article selection procedure](oncotarget-08-70874-g001){#F1}

All these retrospective cohort studies were published in 2013 or later. Nine studies were performed in Asian populations, while 11 articles were based on Western population. Among these 20 studies, 8 studies focused on renal cancer, 4 for UTUC, 3 for bladder cancer, 4 for prostate cancer and 1 for adrenal cancer. The characteristics of these studies are shown in Table [1](#T1){ref-type="table"}.

###### Baseline characteristics of studies included in the meta-analysis

  Author                     Year   Country     No. of patients (M/F)   Age mean±SD/ median (range)   Cut off   Type of cancer   Duration of follow-upmean (range)   Surgery   Staging of TNM   Outcome      QS\#
  -------------------------- ------ ----------- ----------------------- ----------------------------- --------- ---------------- ----------------------------------- --------- ---------------- ------------ ------
  Dirican \[[@R15]\]         2013   Turkey      53(39/14)               61(40-79)                     134       RC               34(5-142)                           P         IV               OS           6
  Fox \[[@R16]\]             2013   Australia   362(268/94)             62(19-84)                     192       RC               NR                                  N         III/IV           OS           7
  Keskin \[[@R17]\]          2014   Turkey      211(135/74)             61.18±11.81                   151       RC               24                                  Y         I/II/III/IV      OS           6
  Gunduz \[[@R18]\]          2015   Turkey      100(79/21)              58(33-95)                     210       RC               32.7                                N         IV               OS,PFS       6
  Lucca \[[@R19]\]           2015   Austria     430(257/173)            65.5(57-73)\*                 145       RC               40(17-73)\*                         Y         I/II/III         DFS          7
  Park \[[@R20]\]            2016   Korea       63(52/11)               63.1(56.0-70.5)\*             150       RC               17.5(9.2-28.4)\*                    N         IV               OS,PFS       5
  Chrom \[[@R21]\]           2017   Poland      321(215/106)            62(22-85)                     157       RC               55.5                                Y         IV               OS           6
  Hu \[[@R22]\]              2017   China       484(278/206)            56(21-81)                     185       RC               36                                  Y         I/II/III/IV      OS           8
  Kim \[[@R23]\]             2015   Korea       277(218/59)             63.7(29.5-90.0)               150\*     UTUC             NR                                  Y         I/II/III         DFS          5
  Huang \[[@R24]\]           2016   China       481(311/170)            NR                            241.2     UTUC             NR                                  Y         I/II/III         OS,CSS       5
  Dalpiaz \[[@R25]\]         2016   USA         180(109/71)             70(62.7-77.2)\*               150       UTUC             30                                  Y         I/II/III         OS,CSS       8
  Song \[[@R26]\]            2016   China       140(86/54)              67(39-81)                     128       UTUC             NR                                  Y         NR               DFS,PFS      7
  Lee \[[@R27]\]             2015   UK          226(174/52)             75 (65-81)\*                  218       BC               NR                                  Y         I/II             OS           7
  Zhang \[[@R28]\]           2016   China       124(100/24)             65(30-78)                     140       BC               NR                                  Y         I/II/III/IV      OS           8
  Kang \[[@R29]\]            2016   Korea       1551(1302/249)          65(57-72)\*                   124       BC               52(27-82)\*                         Y         0a/0is/I         OS,CSS       6
  Langsenlehner \[[@R30]\]   2015   Austria     374(374/0)              68±7.1                        190       PC               87                                  NR        NR               MFS,CSS,OS   6
  Li \[[@R31]\]              2015   China       103(103/0)              66.1±6.9                      150       PC               36                                  NR        NR               OS           5
  Lolli \[[@R32]\]           2016   Italy       230(230/0)              74(45-90)                     210       PC               29(1-55)                            NR        IV               OS           7
  Wang \[[@R33]\]            2016   China       290(29/0)               75(67-79)\*                   117.58    PC               37.0(24.0-50.3)\*                   NR        NR               PFS,CSS,OS   7
  Bagante \[[@R34]\]         2015   USA         79(46/33)               NR                            190       AC               NR                                  Y         I/II/III/IV      RFS,DSS      6

\*The rage is inter-quartile range (IQR). \#quality of study was judged based on the Newcastle-Ottawa Scale.

AC: adrenal cancer; BC: bladder cancer; CSS: cancer-specific survival; DFS: disease free survival; DSS: disease-specific survival; N: none of patients accept the surgery; NR: not reported; MFS: metastases--free survival; OS: overall survival; RFS: recurrence-free survival; P: part of patients accept the surgery; PC: prostate cancer; PFS: progression-free survival; RC: renal cancer; SD: standard deviation; QS: quality of study; UTUC: upper tract urothelial carcinoma; Y: all of patients accept the surgery.

Sixteen studies evaluated the prognostic role of PLR for OS in urologic cancer. The result indicated that a high PLR was significantly associated with worse prognosis of OS in urologic cancer (HR=1.65, 95% CI=1.37-1.99, P\<0.01, I^2^=56%, Figure [2](#F2){ref-type="fig"}). In addition, the almost symmetrical funnel plot confirmed the absence of publication bias in our study (Figure [3](#F3){ref-type="fig"}).

![Forest plot of the hazard ratio for the association between an elevated platelet to lymphocyte ratio and overall survival in patients with urologic cancer](oncotarget-08-70874-g002){#F2}

![Assessment of publication bias using funnel plot analysis](oncotarget-08-70874-g003){#F3}

PLR and renal cancer {#s2_2}
--------------------

One study by Lucca et al.\[[@R19]\] reported that an elevated PLR was not significantly associated with poor DFS in patients with renal cancer (HR=1.78, 95% CI=0.87-3.64, P=0.11). A total of seven studies assessed the association between PLR and OS in renal cancer. The result showed that an elevated PLR was significantly associated with poor OS in renal cancer (HR=1.88, 95% CI=1.39-2.55, P\<0.01, I^2^=61%, Figure [2](#F2){ref-type="fig"}). Subgroup analysis revealed that the significant association between poor OS and elevated PLR can be observed in Western population (HR=1.71, 95% CI=1.45-2.02, P\<0.01, I^2^=0%), but not in Asian populations (HR=4.77, 95% CI=0.51-44.52, P=0.17, I^2^=90%, Table [2](#T2){ref-type="table"}). In other subgroup analysis, the significant association between poor OS and elevated PLR in renal cancer was consistent regardless of treatment, cut-off value, sample size and study quality (Table [2](#T2){ref-type="table"}).

###### Results of overall and subgroup analyses for effects of PLR on overall survival in renal cancer

  Categories           N   Patients   Pooled HR (95% CI)   *P* value   Heterogeneity   
  -------------------- --- ---------- -------------------- ----------- --------------- --------
  Overall effect       7   1594       1.88 (1.39-2.55)     \<0.01      61              0.02
  Region                                                                               
   Asian countries     2   547        4.77 (0.51-44.52)    0.17        90              \<0.01
   Western countries   5   1047       1.71 (1.45-2.02)     \<0.01      0               0.44
  Treaments                                                                            
   Non-sugery          3   525        3.31 (1.37-8.01)     \<0.01      81              \<0.01
   Surgery             3   1016       1.65 (1.25-2.18)     \<0.01      0               0.99
  Cut-off value                                                                        
   ≤157                4   648        2.15 (1.13-4.10)     0.02        78              \<0.01
   \>157               3   946        1.89 (1.53-2.33)     \<0.01      0               0.73
  Sample size                                                                          
   ≤200                3   216        3.09 (1.01-9.47)     0.048       86              \<0.01
   \>200               4   1378       1.78 (1.49-2.13)     \<0.01      0               0.92
  Study quality                                                                        
   ≤6                  5   748        2.14 (1.27-3.62)     \<0.01      73              \<0.01
   \>6                 2   846        1.85 (1.48-2.30)     \<0.01      0               0.69

95%CI: 95% confidence interval; HR: hazard ratio; N: number of studies; Ph: p value of Q test for heterogeneity test.

On the other hand, two studies presented the data on PLR and PFS in metastatic renal cell cancer. This result is similar to that in OS (HR=4.37, 95% CI=2.58-7.40, P\<0.01, I^2^=87%, [Supplementary Figure 1](#SD1){ref-type="supplementary-material"}).

PLR and UTUC {#s2_3}
------------

Two studies assessed the relationship between PLR and OS, CSS, while another two reported the association between PLR and DFS in patients with UTUC. These results indicated that a high PLR was significantly correlated with poor OS (HR=1.69, 95% CI=1.16-2.48, P\<0.01, I^2^=0%, Figure [2](#F2){ref-type="fig"}) and CSS (HR=1.74, 95% CI=1.11-2.71, P=0.01, I^2^=0%, [Supplementary Figure 2](#SD1){ref-type="supplementary-material"}), and we found that an elevated PLR tended to be associated with poor DFS (HR=1.46, 95% CI=0.95-2.25, P=0.09, I^2^=0%).

PLR and bladder cancer {#s2_4}
----------------------

There were three studies reporting the data on PLR and OS in bladder cancer. This result showed that an elevated PLR was not significantly correlated with poor OS (HR=1.02, 95% CI=0.80-1.31, P=0.87, I^2^=0%, Figure [2](#F2){ref-type="fig"}).

PLR and prostate cancer {#s2_5}
-----------------------

Four studies presented the data on PLR and OS, while two studies reported the data on PLR and CSS in patients with prostate cancer. We found that an elevated PLR predicted shorter OS (HR=1.78, 95% CI=1.38-2.30, P\<0.01, I^2^=22%, Figure [2](#F2){ref-type="fig"}) and CSS (HR=2.02, 95% CI=1.24-3.29, P\<0.01, I^2^=31%, [Supplementary Figure 2](#SD1){ref-type="supplementary-material"}) in prostate cancer.

PLR and adrenal cancer {#s2_6}
----------------------

There was only one study assessing the association between PLR and prognosis in adrenal cancer. The result of Bagante \[[@R34]\] showed that a high PLR was not significantly associated with poor RFS (HR=1.72, 95% CI=0.96-3.09, P=0.07) and DSS (HR=0.90, 95% CI=0.47-1.73, P=0.76) in adrenal cancer patients.

DISCUSSION {#s3}
==========

The prognostic role of PLR has been reported in many types of cancers. However, the prognostic value of PLR in urologic cancer patients is still not unclear. To the best of our knowledge, this is the first pooled study to systematically explore the prognostic significance of PLR in patients with urologic cancer.

In our study, the results indicated that an elevated PLR was significantly associated with poor OS and PFS in renal cancer. Moreover, the significant relationship between poor OS and elevated PLR in renal cancer was consistent regardless of treatment, cut-off value, sample size and study quality. Meanwhile, similar results can be observed in UTUC and prostate cancer. Given all this, PLR is a promising prognostic indicator.

The mechanisms about the association between high PLR and poor prognosis of cancer still remain unknown. Growing evidence has reported that platelets can prevent death of cancer cells by natural killer cells, and can secrete angiogenic and tumor growth factors to promote cancer growth, progression and metastasis \[[@R35]--[@R37]\]. Furthermore, it has been reported that thrombocytosis is associated with poor prognosis in renal cancer \[[@R38], [@R39]\]. While lymphocytes are the main components of immune system in the host and can destroy tumor cells and prevent cancer progression \[[@R40]\]. In addition, some studies reported that a low lymphocyte count was an indicator of poor prognostic in patients with renal cancer \[[@R41], [@R42]\]. Therefore, a high PLR, which means relatively elevated platelets counts, and low lymphocyte counts may predict poor prognosis in renal cancer.

In this study, most of cohort studies which focus on the role of PLR in renal cancer in this review are from Western countries. Our result indicated that in renal cancer, the significant association between poor OS and elevated PLR can be observed in Western population, but not in Asian populations. It is noted that only two studies performed in Asian countries were included in our study. More future studies should be performed to elucidate the prognostic role of PLR in renal cancer for Asian populations.

On the other hand, in this study, our result showed that an elevated PLR was significantly associated with poor OS in renal cancer and prostate cancer. But the significant association could not been observed in bladder cancer. We think that compared with renal cancer and prostate cancer, bladder cancer is a relatively localized disease. Thus, renal cancer and prostate cancer may be more influenced by the systemic inflammatory response than bladder cancer. Though our result showed a significant association between an elevated PLR and poor OS in UTUC, we should note that only 2 studies about UTUC and 3 studies about bladder cancer were included in our study. More studies are required to confirm the role of PLR in bladder cancer and UTUC in the future.

NLR is a well-known indicator for prognosis in cancer patients. NLR was reported to may represent a balance between procancer inflammatory reaction and anticancer immune function \[[@R43]\]. NLR have been reported to be a prognostic predictor of urologic tumors such as bladder cancer, renal cell cancer, UTUC and prostate cancer \[[@R6]--[@R10]\]. While our result indicated that an elevated PLR was not significantly associated with poor OS in bladder cancer. We think that neutrophils may play a more important role in cancer prognosis than platelets, thus may partly explain this result, and it needs to be confirmed in the future.

In our study, the cut-off value PLR in these included studies varied from 117.58 to 241.2. Controversy still exists on the optimal cut-off value of PLR in predicting prognosis for cancer patients. In this present study, we split studies which focus on renal cancer into two groups according to the median value of PLR, the results confirmed that a low PLR is a poor prognostic predictor of OS in both groups. High-quality and well-designed studies are required in the future to set the optimal cut-off value of PLR.

Several limitations exist in our study. First, all these included studies were retrospective studies. Second, heterogeneity among these studies were relatively large and this might be caused by different countries, different types of cancers or/and other factors. Third, due to the related limited number of included studies, we were not able to perform other subgroup analyses.

In conclusion, an elevated PLR was significantly associated with poor survival in renal cancer and prostate cancer. Future studies are warranted to further clarify this association in UTUC, bladder cancer and adrenal cancer.

MATERIALS AND METHODS {#s4}
=====================

Search strategy {#s4_1}
---------------

Two authors (Jianfeng Wang And Jianbin Bi) searched PubMed, Embase, and Web of Science independently for relevant articles published up to March 5, 2017. The main terms were \[(bladder OR vesical OR renal OR kidney OR prostate OR prostatic OR urothelial OR urothelium OR adrenal OR urinary OR urology OR urologic) AND (cancer OR neoplasm OR carcinoma OR malignancy)\] and ("platelet-lymphocyte ratio" OR "platelet to lymphocyte ratio" OR "platelet lymphocyte ratio" OR PLR). Moreover, potentially searches were also performed by screening the references of relevant review or selected articles.

Inclusion and exclusion criteria {#s4_2}
--------------------------------

In this study, PICO criteria (population, intervention, comparison and outcomes) was used to select eligible articles: (1) population: patients who were diagnosed with urologic cancer based on histopathologic examination; (2) intervention: pretreatment or preoperative PLR; (3) comparison: elevated PLR vs. low PLR; (4) outcomes: cancer-specific survival (CSS), disease-free survival (DFS), metastases--free survival (MFS), overall survival (OS), progression-free survival (PFS) and/or recurrence-free survival (RFS). Studies were not included if it was impossible to estimate outcomes from their original data. Case reports and abstracts from meetings were excluded.

Data extraction {#s4_3}
---------------

The following data was extracted from each study: name of first author, year of publication, country of patients, sample size, patient characteristics (including gender, age, type of cancer, duration of follow-up and tumor stage), treatment details, cut-off value of PLR and hazard ratio (HR) with associated 95% confidence intervals (CI) for survival.

Statistical analysis {#s4_4}
--------------------

The pooled HR and 95 % CI were estimated using the inverse variance method with the Random-effects model. The method of Tierney was used to estimate the HR and 95% CI for those studies in which the HR cannot be extracted directly \[[@R44]\]. Cochran's Q test and I^2^ statistics was used to assess statistical heterogeneity in this study \[[@R45]\]. The Newcastle-Ottawa quality assessment scale (NOS) was used to assess the quality of the studies \[[@R46]\]. Publication bias was evaluated by funnel plot. All the data analyses were conducted using the Review Manager 5.2 software. A P value less than 0.05 was considered as statistically significant.
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